PPT-Elimination of HIV-1 latently infected cells by PKC agonist

gnidimacrin alone and in combination with an HDAC inhibitor Li Huang Duke University North Carolina USA Towards an HIV cure Latent HIV reservoirs Shock and kill strategy. Case 1:09-md-02058-PKC Document 983 Filed 12/04/13 Page 3 of 6 Mwilm COHEN & ORESSER, LLP Lawrence T. Grosser Daniel H. Tabok New York, NY 10022 Conse1for Defendant Bank ofArnerlca ROJ3B1NS RUSSELL E The . P. erfect Storm. Presented at . the Sixth . Tri-Divisional HIV/AIDS meeting September 2013 . by Allan R. Handysides M.B.,. Ch.B. .. FRCPC, FRCSC, FACOG.. Taken from the book by Jacques Pepin . be cleared by CTL . ?. Una O’. Doherty. June 29, 2013. Infect (X4 or R5 HIV). Culture 3-4d. Measure total & integrated HIV DNA. Our experimental system. O. ’. Doherty U . J. Virol.. 2000. O. SOS ENaCPIP3 C3G P IP 3 3G -P GAB1 Insuli PDK1/2 PKC Akt p70 PKC GA G p85 JAK NIK p PI3K Akt Tsc1 SOCS3 Shc NI K N GRB2 GRB 2 IRS-1 Fyn GRB10 Ras c-Raf MEK1/2 ERK PDE3B PKA SGK JNK SHP2 IRS-1 PTEN HIV Cure Research Training Curriculum. Latency Reversing Agents . Module by:. Scientific . Leads. : David M. Margolis (CARE) and Sharon Lewin (DARE. ). . Community Leads. : Cipri Martinez (DARE) and David Palm (CARE). .. PRESENTERS:. MOHAMED M. NOORANY- . MBChB. V (MUSOM). MUKOYA AQUINATA (. Sr. )- . MBChB. V (MUSOM). FACILITATORS:. DR. JAMES OBONDI (Chief Orthopedic Specialist). DR. STEVE OKELLO (. MBChB. , MMED registrar- . infected. ~33 million infected. ~2.1 million. deaths/year (AIDS). . HBV . and . HIV are both . chronic . viral . infections. Lifelong treatment is necessary. . None of the >25 approved drugs for HIV or HBV can clear the infection.. Co-Infection – Florida, . 2014. . STD and Hepatitis Section in collaboration with HIV/AIDS Section – Surveillance Unit . Division of Disease Control and Health Protection. HIV Disease data from 1981 through December . Co-Infection – Florida, . 2013. . STD and Hepatitis Section in collaboration with HIV/AIDS Section – Surveillance Unit . Division of Disease Control and Health Protection. HIV Disease data from 1981 through December . AIDS- Acquired . I. mmune . D. eficiency Syndrome, is a serious viral disease that destroys the body’s immune . system. HIV-The virus (Human Immunodeficiency Virus) that causes AIDS.. Of the 40,000 new HIV infections each year, half of those occur in people younger than 25 years old. Gilead Sciences. Foster City, CA , USA. Activating. PKC-. ε . induces HIV. expression with improved tolerability. This study was funded by Gilead Sciences, USA. Protein Kinase C(PKC) agonists activate latent HIV, but have limited clinical utility due to toxicity. . Archana Vidya Boopathy,. 1. Anurag Nekkalapudi,. 1. Bhawna Sharma,. 1. Sophie Schulha,. 2. . Raphaela. Wimmer,. 2. Debi Jin,. 1. Janette Sung,. 1. Jeffrey Murry,. 1. Mark Nagel,. 1. Brian Carr,. Objectives. Discuss the pharmacology of . catecholamines. Classify & describe adrenergic α-agonists including actions, therapeutic uses & adverse. reactions.. Classify & describe adrenergic β-agonists including actions, therapeutic uses & adverse. David L. Thomas, MD, MPH. Professor of Medicine. The Johns Hopkins Medical Institutions. Baltimore, Maryland . Financial Relationships With Commercial Entities. Dr Thomas has no relevant financial affiliations to disclose. (Updated 11/12/18).